Crinetics Pharmaceuticals reported Q2 2026 results with initial revenue from PALSONIFY commercial sales and ongoing clinical progression of key pipeline candidates including paltusotine in carcinoid syndrome and atumelnant in congenital adrenal hyperplasia. The company awaits EMA marketing authorization following a positive CHMP opinion and is building U.S. commercial infrastructure. A pending merger with Vertex Pharmaceuticals introduces potential execution risks as the transaction nears completion conditional upon regulatory and shareholder approvals. Crinetics’ proprietary small molecule GPCR approach underpins a differentiated oral somatostatin receptor ligand offering amid a competitive endocrine-focused biotech landscape. The company’s cash position supports continued R&D investment and commercial scale-up through critical near-term milestones.